Heterocyclic NR2B Antagonists for Targeted NMDA Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression, bipolar disorder, migraine, pain, and peripheral symptoms of dementia do not effectively target the NMDA receptor containing the NR2B subunit, which is crucial for central nervous system function.
Innovation Solution
Development of heterocyclic compounds that act as antagonists on the NMDA receptor containing the NR2B subunit, providing prophylactic or therapeutic agents for these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for depression, bipolar disorder, migraine, pain, and peripheral symptoms of dementia are used, then existing therapeutic options are available, but effective solutions are lacking particularly for NMDA receptor containing NR2B subunit-related conditions
Solution Approach 1:
The patent modifies the chemical structure of NMDA receptor antagonists by changing specific parameters (substituents at positions R1-R6, heterocyclic ring configurations, and stereochemical configurations at C5 and C6) to create compounds with enhanced affinity and selectivity for the NR2B subunit, thereby improving treatment effectiveness for conditions mediated by this specific receptor subtype
2Reliability
If NMDA receptor containing NR2B subunit is targeted, then central nervous system function and neurotransmission can be modulated, but the complexity of the receptor structure and its subunits increases the difficulty of developing effective antagonists
Solution Approach 1:
The patent focuses on creating antagonists with specific local structural features (particular heterocyclic ring arrangements at positions B1-B3 and specific substituent patterns at R1-R6) that are optimized for interacting with the NR2B subunit binding site, allowing selective modulation of this particular receptor subtype without requiring complete characterization of the entire NMDA receptor complex
Solution Approach 2:
The NMDA receptor is segmented into different subunits (NR1, NR2A, NR2B, NR2C, NR2D), and the patent develops antagonists that specifically target the NR2B subunit segment, allowing independent optimization of binding affinity and selectivity for this particular functional unit without needing to address the entire receptor structure
Data Source
AI summary
A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.